Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

@article{Ibrahim2010EfficacyOT,
  title={Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.},
  author={Amr R Ibrahim and Christos Paliompeis and Marco Bua and Dragana Milojkovic and Richard M. Szydlo and Jamshid S Khorashad and Letizia Foroni and Alistair G. Reid and Hugues de Lavallade and K Rezvani and Francesco Dazzi and Jane F. Apperley and John M. Goldman and D. W. Marin},
  journal={Blood},
  year={2010},
  volume={116 25},
  pages={
          5497-500
        }
}
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic responses on third-line therapy. Younger age and the achievement of a cytogenetic response on second… CONTINUE READING
14 Citations
13 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia

  • D Milojkovic, E Nicholson, JF Apperley
  • Haematologica
  • 2010

in chronic phase with resistance or intolerance to imatinib

  • RJ Garg, H Kantarjian, S O’Brien
  • 2008

Similar Papers

Loading similar papers…